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Abstract
The aim of this study is to assess nucleoprotein expression of IKZF1/3 in patients with relapsed/refractory multiple
myeloma (MM) who received lenalidomide-based therapy and correlated them with their clinical outcomes. A total
of 50 patients diagnosed with MM were entered in the study with the median follow-up of 86.4 months. By
immunohistochemistry (IHC), IKZF1 and IKZF3 were expressed in 72 and 58% of the cases, respectively. IKZF1
and IKZF3 expressions were associated with longer median progression free survival (P = 0.0029 and P < 0.0001) and
overall survival (P = 0.0014 and P < 0.0001). IKZF3 expression also appears predicted a favorable response to the
lenalidomide-based therapy.
It has been demonstrated that lenalidomide causes se-
lective degradation of IKZF1 (ikaros) and IKZF3 (aiolos)
which are two essential transcription factors for mye-
loma cell proliferation [1, 2]. This anti-proliferative effect
is mediated by downregulation of c-Myc and interferon
regulatory factor 4 (IRF4) [3]. In particular, IKZF3 regu-
lates expression of IRF4 which is linked with lenalido-
mide activity [4–6]. However, the clinical relevance of
IKZF1/IKZF3 expressions in myeloma patients has not
been established. Thus, we examined nuclear expression
of IKZF1/3 and its correlation with clinical outcomes in
patients with relapsed/refractory MM who received lena-
lidomide therapy.
A total of 50 patients diagnosed with MM in our
institution were entered in the study. All had received
lenalidomide-based therapy (lenalidomide plus dexa-
methasone) after relapse. The median follow-up after
diagnosis was 7.2 years. The relevant clinical and labora-
tory features are summarized in Table 1.
CD138 and IKZF1/3 immunohistochemical (IHC) stain-
ing were performed on the bone marrow aspiration/biopsy
specimens taken before starting lenalidomide. CD138
positive myeloma cell aggregates (Additional file 1:
Figure S1B) were examined for IKZF1/3 expression
(Additional file 1: Figure S1C, D). H-score method
(range 0–300) according to staining intensity and per-
centage of myeloma cells was applied. The median H-
scores for IKZF1 and IKZF3 were 150 and 200, respectively,
and high or low expression was based on above or below
the median H-score (Fig. 1a).
Of the 50 MM cases, IKZF1 and IKZF3 were
expressed in 36 (72%) and 29 (58%) cases, respectively.
Twenty-eight of 29 cases (97%) with high IKZF3 expres-
sion also showed IKZF1 positivity (P < 0.0001). High
IKZF3 (P = 0.0025), but not IKZF1 expression (P = 0.094)
was strongly correlated with clinical response (Fig. 1b).
Patients with high IKZF1 or IKZF3 expression showed
longer PFS (median 22.6 vs. 6.3 months, P = 0.0029; or
43.2 vs. 3.7 months; P < 0.0001) and OS (median 44.3 vs.
12.1 months, P = 0.0014; or 47 vs. 12.1 months;
P < 0.0001) (Fig. 1c–f ), respectively. In addition, the
group with both high IKZF1/3 expression was associated
with longer PFS (median 31.8 vs. 3.9 months, P < 0.0001)
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and OS (median OS 58.7 vs. 12.1 months, P < 0.0001),
whereas the group with both low expression was correlated
with shorter PFS (median 4.1 vs. 26.8 months, P = 0.0003)
and OS (median 12.1 vs. 46.2 months, P = 0.0002). Of note,
high IKZF3 expression appeared associated with higher
creatinine but with less lytic lesion, and by multivariable
analysis, high IKZF3 expression remained an independent
poor risk factor for PFS (P < 0.0001) and OS (P < 0.0001)
after adjusting these two covariates. There was no signifi-
cant association between IKZF1/3 protein expression and
other clinical or biological risk factors (Table 1).
Previous studies have indicated controversial results
about the relationship between Ikaros expression level
and resistance to lenalidomide. Lu et al. [7] found that
some MM cell lines with higher expressions of IKZF1 or
IKZF3 showed resistance to the drug; in contrast,
















Sex (M/F) 31/19 23/13 8/6 0.6590 19/10 12/9 0.5471
Age (year), median (range) 59(41–75) 57 (41–73) 59 (45–75) 0.6416 57 (41–69) 59 (44–75) 0.3105
International staging system, no. (%) 0.1785 0.1448
I 24 (48) 14 (38.89) 10 (71.43) 11 (37.93) 13 (61.90)
Il 18 (36) 14 (38.89) 4 (28.57) 11 (37.93) 7 (33.33)
III 5 (10) 5 (13.89) 0 (0) 5 (17.24) 0 (0)
NA 3 (6) 3 (8.33) 0 (0) 2 (6.90) 1 (4.76)
Hemoglobin concentration (g/L),
median (range)
105 (76–147) 106 (76–147) 103 (86–132) 0.6027 104 (76–147) 107 (85–141) 0.3121
Calcium (mmol/L), median (range) 2.25 (1.98–2.57) 2.26 (1.98–2.57) 2.23 (2–2.55) 0.8162 2.25 (1.98–2.57) 2.25 (2–2.55) 0.7160
Creatinine (μmol/L), median (range) 76 (32–360) 86 (40–360) 67.58 (32–126) 0.0569 88 (57–360) 66 (32–126) 0.0072
Having lytic lesions, number of
patients (%)
27 (54) 18 (50) 9 (64.29) 0.3628 12 (41.38) 15 (71.43) 0.0354
B2-microglobulin (mg/L) 3.08 (0.51–16.76) 3.50 (0.51–16.76) 2.96 (1.35–5.16) 0.5817 3.62 (0.51–16.76) 2.82 (1.07–5.16) 0.1293
Albumin (gr/L) 40.5 (28–47) 41 (28–47) 39 (29–44) 0.6151 41 (28–47) 40 (29–44) 0.9078
Prior therapies, no. (%)
≥3 23 (46) 15 (41.67) 8 (57.14) 0.3242 12 (41.38) 11 (52.38) 0.4411
Thalidomide 29 (58) 22 (61.11) 7 (50) 0.4748 15 (51.72) 14 (66.67) 0.2907
Bortezomib 21 (42) 14 (38.89) 7 (50) 0.4748 12 (41.38) 9(42.86) 0.9168
ASCT 40 (80) 31 (86.11) 9 (64.29) 0.1180 25 (86.21) 15 (71.43) 0.2859
Response to lenalidomide plus dexamethasone, no. (%)
Responsive 41 (82) 32 (88.89) 9 (64.29) 0.094 28 (96.55) 13 (61.90) 0.0025
Non-responsive 9 (18) 4 (11.11) 5 (35.71) 1 (3.45) 8 (38.1)
Cytogenetics, no. (%)
del (13q) 1.0000 0.7243
Positive 13 (26) 9 (25) 4 (28.57) 7 (24.14) 6 (28.57)
Negative 37 (74) 27 (75) 10 (71.43) 22 (75.86) 15 (71.43)
del (17p) 0.1966 0.2552
Positive 8 (16) 4 (11.11) 4 (28.57) 3 (10.34) 5 (23.81)
Negative 42 (84) 32 (89) 10 (71.43) 26 (89.66) 16 (76.19)
t(4;14) 1.0000 0.7163
Positive 9 (18) 7 (19.44) 2 (14.29) 6 (20.69) 3 (14.29)
Negative 41 (82) 29 (80.56) 12 (85.71) 23 (79.31) 18(85.71)
amp(1q21) 0.1228 0.1283
Positive 20 (40) 12 (33.33) 8 (57.14) 9 (31.03) 11 (52.38)
Negative 30 (60) 24 (66.67) 6 (42.86) 20(68.97) 10 (47.62)
Pourabdollah et al. Journal of Hematology & Oncology  (2016) 9:123 Page 2 of 4
Zhu et al. [8] showed that low IKZF1 transcript levels
were correlated with poor response to IMiDs. They
also found that higher IKZF1 but not IKZF3 gene ex-
pression was associated with better OS. Our study
demonstrates that expression of IKZF1/3 proteins (es-
pecially IKZF3) is correlated with better outcome in
refractory MM patients treated with lenalidomide. A pos-
sible explanation for this observation is that in the pres-
ence of high IKZF1/3 levels, myeloma cells are more
dependent on IKZF-associated signaling for proliferation.
Particularly, IKZF3 is linked to plasma cell development
and lenalidomide efficacy as IKZF3 is specifically required
for the generation of long-lived plasma cells and it has
been shown to be reduced by lenalidomide [9, 10].
To the best of our knowledge, this is the first report to
show a correlation between IKZF1/3 protein expressions
and clinical outcomes in refractory MM treated with
lenalidomide. However, this study has limitations as it is
retrospective with limited sample size. Nevertheless, as par-
affin IHC is routinely available, robust, and inexpensive, if
Fig. 1 Expression of IKZF1 and IKZF3 proteins in tumor cells, measured by H-score (a) and their correlation with clinical response (b). Progression
free survival (PFS) and overall survival (OS) in relation to IKZF1 nuclear expression (c, d), and in relation to IKZF3 nuclear expression (e, f) detected
by IHC, respectively
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confirmed in a larger prospective study, IKZF1/3 (especially
IKZF3) immunostaining can be readily adopted in clinical
practice for prediction of drug response and clinical out-
comes in MM patients receiving lenalidomide therapy.
Additional file
Additional file 1: Figure S1. Bone marrow biopsy from a patient with
MM. (A) H&E stain, (B) CD138 for myeloma cells, (C) Nuclear expression of
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